WALTHAM, Mass. / Feb 20, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences in March 2025:
46th Annual Raymond James Institutional Investor Conference
Monday, March 3, 2025
7:30 a.m. ET - Max Krakowiak, senior vice president and chief financial officer
TD Cowen 45th Annual Health Care Conference
Tuesday, March 4, 2025
9:10 a.m. ET - Prahlad Singh, president and chief executive officer
Leerink Partners Global Healthcare Conference
Tuesday, March 11, 2025
8:00 a.m. ET - Prahlad Singh
KeyBanc Capital Markets Healthcare Forum
Wednesday, March 19, 2025
9:00 a.m. ET - Steve Willoughby, senior vice president, investor relations, ESG, risk
Attendees will receive an update on the Company and its strategic priorities.
Live audio webcasts will be available on the Events section of the Company’s website. Replays of the presentations will be posted on the Revvity Investor Relations website after the events and will be available for at least 30 days.
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2024 revenue of more than $2.7 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.
Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.
| Last Trade: | US$111.52 |
| Daily Change: | -1.40 -1.24 |
| Daily Volume: | 952,373 |
| Market Cap: | US$13.570B |
January 13, 2025 January 12, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
